Compare Regeneron Pharmaceuticals Inc (REGN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tyson Foods, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Tyson Foods, Inc. trades at $57.12 (market cap $20.09B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.5× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| REGN | TSN | |
|---|---|---|
Market Cap | $70.79B | $20.09B |
Sector | Health | Consumer Staples |
52-Week High | $812.27 | $68.75 |
52-Week Low | $545.46 | $50.72 |
Enterprise Value | $64.74B | $27.67B |
Dividend Yield | 0.56% | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Tyson Foods (TSN) trades at $57.05, down 1.25% with neutral technical indicators. The company shows stable revenue near $54B but thin margins, with a 0.81% net income margin and elevated P/E of 45.67. Recent earnings beat expectations in Q1 2026, while analyst consensus is mixed with a $68.80 price target. Dividend payments continue at $0.51 quarterly.
TSN offers modest growth potential with analyst upside but faces margin pressure and competitive challenges. The stock's valuation appears stretched relative to earnings, while consistent dividends provide income support. Key risks include commodity cost volatility and execution in the competitive protein market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
